Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Annexon, Inc. stock logo
ANNX
Annexon
$2.58
-7.9%
$2.29
$1.29
$7.85
$307.20M1.31.48 million shs1.59 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$18.77
-1.5%
$19.79
$16.67
$22.00
$1.20B0.37704,540 shs764,766 shs
Omeros Corporation stock logo
OMER
Omeros
$3.65
+5.5%
$3.66
$2.95
$13.60
$202.73M2.16737,350 shs954,253 shs
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$1.50
-3.8%
$1.41
$0.89
$4.29
$66.91M0.84248,986 shs79,010 shs
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$18.44
$18.12
$5.80
$20.96
$1.94B2.081.87 million shs8 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Annexon, Inc. stock logo
ANNX
Annexon
-7.86%-12.69%+2.38%+73.15%-48.81%
Innoviva, Inc. stock logo
INVA
Innoviva
-1.52%-2.24%-12.17%+7.13%+11.86%
Omeros Corporation stock logo
OMER
Omeros
+5.49%+14.03%+0.83%-45.77%-9.88%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-3.85%+9.49%+4.17%+66.67%-56.52%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Annexon, Inc. stock logo
ANNX
Annexon
2.573 of 5 stars
3.52.00.00.02.22.50.6
Innoviva, Inc. stock logo
INVA
Innoviva
4.2141 of 5 stars
3.50.00.04.22.81.71.9
Omeros Corporation stock logo
OMER
Omeros
3.5776 of 5 stars
3.40.00.04.41.71.70.6
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.4727 of 5 stars
3.33.00.00.01.62.50.6
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Annexon, Inc. stock logo
ANNX
Annexon
3.00
Buy$12.50384.50% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$40.50115.77% Upside
Omeros Corporation stock logo
OMER
Omeros
2.83
Moderate Buy$18.00393.15% Upside
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
2.50
Moderate Buy$4.50200.00% Upside
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INVA, TRIL, RPTX, OMER, and ANNX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/11/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$26.00
6/30/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00
6/27/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
6/10/2025
Omeros Corporation stock logo
OMER
Omeros
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$9.00
5/16/2025
Omeros Corporation stock logo
OMER
Omeros
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingHold ➝ Hold
5/14/2025
Annexon, Inc. stock logo
ANNX
Annexon
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$20.00 ➝ $14.00
5/13/2025
Annexon, Inc. stock logo
ANNX
Annexon
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$16.00 ➝ $11.00
5/13/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
5/7/2025
Omeros Corporation stock logo
OMER
Omeros
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$36.00 ➝ $36.00
(Data available from 7/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/A$2.75 per shareN/A
Innoviva, Inc. stock logo
INVA
Innoviva
$358.71M3.29$3.38 per share5.56$11.03 per share1.70
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/A($3.15) per shareN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
$53.48M1.20N/AN/A$3.56 per share0.42
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
$150K12,907.39N/AN/A$2.56 per share7.20
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Annexon, Inc. stock logo
ANNX
Annexon
-$138.20M-$1.18N/AN/AN/AN/A-54.45%-46.56%8/11/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$23.39M-$1.01N/A12.11N/A-16.15%15.77%8.41%7/29/2025 (Estimated)
Omeros Corporation stock logo
OMER
Omeros
-$156.82M-$2.65N/AN/AN/AN/AN/A-59.68%8/6/2025 (Estimated)
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
-$84.69M-$3.01N/AN/AN/AN/A-78.12%-67.11%N/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
-$59.35M$0.6229.74N/AN/AN/A-23.31%-18.66%N/A

Latest INVA, TRIL, RPTX, OMER, and ANNX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.46N/AN/AN/AN/AN/A
7/29/2025Q2 2025
Innoviva, Inc. stock logo
INVA
Innoviva
$0.43N/AN/AN/A$87.10 millionN/A
5/15/2025Q1 2025
Omeros Corporation stock logo
OMER
Omeros
-$0.60-$0.65-$0.05-$0.58$0.40 millionN/A
5/12/2025Q1 2025
Annexon, Inc. stock logo
ANNX
Annexon
-$0.30-$0.37-$0.07-$0.37N/AN/A
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Annexon, Inc. stock logo
ANNX
Annexon
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Omeros Corporation stock logo
OMER
Omeros
N/AN/AN/AN/AN/A
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/AN/AN/AN/AN/A
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Annexon, Inc. stock logo
ANNX
Annexon
N/A
7.99
7.99
Innoviva, Inc. stock logo
INVA
Innoviva
0.40
2.48
2.30
Omeros Corporation stock logo
OMER
Omeros
N/A
1.16
1.16
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
N/A
7.42
7.42
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
N/A
19.82
19.82

Institutional Ownership

CompanyInstitutional Ownership
Annexon, Inc. stock logo
ANNX
Annexon
N/A
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Omeros Corporation stock logo
OMER
Omeros
48.79%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
85.09%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
87.15%

Insider Ownership

CompanyInsider Ownership
Annexon, Inc. stock logo
ANNX
Annexon
11.87%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
Omeros Corporation stock logo
OMER
Omeros
12.90%
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
11.50%
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
9.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Annexon, Inc. stock logo
ANNX
Annexon
60109.71 million96.69 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.36 millionOptionable
Omeros Corporation stock logo
OMER
Omeros
21058.59 million51.04 millionOptionable
Repare Therapeutics Inc. stock logo
RPTX
Repare Therapeutics
18042.89 million37.96 millionOptionable
Trillium Therapeutics Inc. stock logo
TRIL
Trillium Therapeutics
33105.00 million95.44 millionOptionable

Recent News About These Companies

Trillium Therapeutics Stock Price History
TTI Consumer Power Tools, Inc. is Seeking an IP Paralegal
Advances in Drug Discovery & Development 2024
Cachet Bicycle shakes off COVID
BridgeBio raises $1.25bn, and other biotech financings
Ratio Therapeutics Raises $50M in Series B Financing
Leukemia Therapeutics Global Market Report 2023

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Annexon stock logo

Annexon NASDAQ:ANNX

$2.58 -0.22 (-7.86%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$2.71 +0.13 (+5.04%)
As of 07/11/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Innoviva stock logo

Innoviva NASDAQ:INVA

$18.77 -0.29 (-1.52%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$17.86 -0.91 (-4.84%)
As of 07/11/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Omeros stock logo

Omeros NASDAQ:OMER

$3.65 +0.19 (+5.49%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$3.68 +0.04 (+0.96%)
As of 07/11/2025 06:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Repare Therapeutics stock logo

Repare Therapeutics NASDAQ:RPTX

$1.50 -0.06 (-3.85%)
Closing price 07/11/2025 04:00 PM Eastern
Extended Trading
$1.51 +0.01 (+0.67%)
As of 07/11/2025 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

Trillium Therapeutics stock logo

Trillium Therapeutics NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.